113 related articles for article (PubMed ID: 17910313)
1. Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma.
Morrison VA
Oncology (Williston Park); 2007 Aug; 21(9):1104-10. PubMed ID: 17910313
[TBL] [Abstract][Full Text] [Related]
2. Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas.
Morrison VA
Oncology (Williston Park); 2007 Sep; 21(10):1191-8; discussion 1198-1208, 1210. PubMed ID: 17926798
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.
Ninan MJ; Morrison VA
Expert Rev Hematol; 2009 Apr; 2(2):173-82. PubMed ID: 21083450
[TBL] [Abstract][Full Text] [Related]
4. Non-Hodgkin's lymphoma in the elderly.
Caimi PF; Barr PM; Berger NA; Lazarus HM
Drugs Aging; 2010 Mar; 27(3):211-38. PubMed ID: 20210368
[TBL] [Abstract][Full Text] [Related]
5. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
6. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
7. [Non-Hodgkin lymphoma in the elderly].
Dupuis J; Haioun C
Bull Cancer; 2008 May; 95 FMC Onco():F79-83. PubMed ID: 18511372
[TBL] [Abstract][Full Text] [Related]
8. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
12. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
Traullé C; Coiffier BB
Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002
[TBL] [Abstract][Full Text] [Related]
13. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
Dawson K
J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
16. The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis.
Cheung MC; Imrie KR; Friedlich J; Buckstein R; Lathia N; Mittmann N
Psychooncology; 2009 May; 18(5):554-9. PubMed ID: 18942670
[TBL] [Abstract][Full Text] [Related]
17. Cranio-maxillofacial non-Hodgkin's lymphoma: clinical and histological presentation.
Scherfler S; Freier K; Seeberger R; Bacon C; Hoffmann J; Thiele OC
J Craniomaxillofac Surg; 2012 Oct; 40(7):e211-3. PubMed ID: 22093243
[TBL] [Abstract][Full Text] [Related]
18. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
Al-Tourah AJ; Gill KK; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Sehn LH; Shenkier TN; Gascoyne RD; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5165-9. PubMed ID: 18838711
[TBL] [Abstract][Full Text] [Related]
19. Rituxan delays disease progression in indolent non-Hodgkin's lymphoma.
Oncology (Williston Park); 2002 Nov; 16(11):1472. PubMed ID: 12469926
[No Abstract] [Full Text] [Related]
20. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
